New drug combo aims to beat Leukemia's resistance to treatment
NCT ID NCT03513562
Summary
This study is testing whether adding a drug called venetoclax to an existing treatment (ibrutinib) can help patients with chronic lymphocytic leukemia (CLL) whose cancer has become resistant. The goal is to eliminate the genetic changes that cause resistance and better control the disease. The trial involves 28 participants who are already taking ibrutinib but have developed specific resistance mutations.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.